Assuming they can keep up the current pace. Wouldn't it be nice to hear about an expansion of the European launch, accompanied by a few testimonials? And Japan should kick in sometime--it's been over a year now. Through all the travails of the current candidate, there has never been even a suggestion that it is not meeting the non-inferiority standard of the trial.
Bruno, I agree the trial will be completely enrolled by next qtrly earnings call. The offering is to be completed today, so I see (and the charts agree) that we will trend up from here. Next resistance levels 1.60, 2.0 and 2.20. Having the money now to build inventory for EU and expand KOL sites and open to more distributors will get things moving. Century remains the wildcard since no one is any expectation of the approval by the Japanese Ministry of Health.